| 03/24 | Chugai Pharmaceutical : Receives Forerunner Designation for Enspryng in Myelin Oligodendro.. | PU |
| 03/14 | Chugai Pharmaceutical : Galderma Announces Updates on Nemolizumab Development | PU |
| 02/28 | Chugai Pharmaceutical : Files for Additional Indication of Actemra for Cytokine Release Sy.. | PU |
| 02/24 | Chugai Pharmaceutical : Notice of the 112th Annual General Meeting and Meeting Materials | PU |
| 02/22 | Chugai Pharmaceutical : Other matters regarding measures for electronic provision of mater.. | PU |
| 02/13 | Chugai Pharmaceutical Co., Ltd. - Support for the Earthquake in Turkey and Syria | AQ |
| 02/07 | Chugai Pharmaceutical : Announces Positive Data from Global Phase III Program for Crovalim.. | PU |
| 02/02 | Chugai's Hemlibra Approved by the European Commission to Treat People with Moderate Hem.. | AQ |
| 02/02 | Chugai Pharmaceutical : Full Year Results (Jan-Dec 2022) | PU |
| 02/01 | Chugai Pharmaceutical : Hemlibra Approved by the European Commission to Treat People with .. | PU |
| 2022 | Chugai Pharmaceutical : The Launch of Chugai's New TV Commercial Featuring Tori Matsuzaka .. | PU |
| 2022 | CHMP Recommends Expansion of EU Label for Hemlibra to Include People with Moderate Hemo.. | AQ |
| 2022 | CHMP recommends expansion of EU label for Hemlibra to include people with moderate haem.. | AQ |
| 2022 | Interim data from phase III study presented at ASH 2022 show Hemlibra achieved meaningf.. | AQ |
| 2022 | Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment | AQ |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Transfer and Future Marketing of Osteoporosis Agent B.. | AQ |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Organizational and Personnel Changes | AQ |
| 2022 | Chugai Pharmaceutical : Organizational and Personnel Changes | PU |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Contribution of Para-transit Vehicles to Welfare Serv.. | AQ |
| 2022 | Chugai Pharmaceutical and IBM Japan Initiate Operation of Digital Infrastructure at Uki.. | AQ |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Purchase of Land for Business in Ukima | AQ |
| 2022 | Chugai Pharmaceutical : Purchase of Land for Business in Ukima | PU |
| 2022 | Chugai Announces 2022 3rd Quarter Results | AQ |
| 2022 | Chugai Pharmaceutical : Supplementary Materials | PU |
| 2022 | Construction of Chugai's New Research Center 'Chugai Life Science Park Yokohama' Reache.. | AQ |
| 2022 | Chugai Pharmaceutical : 3Q Results (Jan-Sep 2022) | PU |
| 2022 | Chugai Pharmaceutical : Construction of Chugai's New Research Center “Chugai Life Sc.. | PU |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Season's Fifteenth Typhoon | AQ |
| 2022 | Chugai Pharmaceutical : Files New Drug Application in Japan for Fixed-Dose Subcutaneous Co.. | PU |
| 2022 | Chugai Pharmaceutical : Summary | PU |
| 2022 | Chugai Pharmaceutical : Obtains Regulatory Approval for POLIVY for Additional Indication o.. | PU |
| 2022 | Chugai Pharmaceutical : and Noile-Immune Biotech Enter into a License Agreement for Noile-.. | PU |
| 2022 | Chugai Pharmaceutical : Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tabl.. | PU |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priorit.. | AQ |
| 2022 | Chugai Pharmaceutical : Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in C.. | PU |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig.. | AQ |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Maruho Launched in Japan the Anti-IL-31 Receptor a Hu.. | AQ |
| 2022 | Chugai Pharmaceutical : Notice of the Settlement of Patent Infringement Litigation in the .. | PU |
| 2022 | Chugai Pharmaceutical : Maruho Launched in Japan the Anti-IL-31 Receptor A Humanized Monoc.. | PU |
| 2022 | Chugai Pharmaceutical : Script (including Q&A) | PU |
| 2022 | Chugai Pharmaceutical Co., Ltd. - F. Hoffmann-La Roche Announces Half Year Results 2022 | AQ |
| 2022 | Chugai Pharmaceutical : CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited)(for the sec.. | PU |
| 2022 | Chugai Pharmaceutical : Supplementary Materials for Consolidated Financial Results for the.. | PU |
| 2022 | Chugai Pharmaceutical : Announces 2022 Half Year Results | PU |
| 2022 | Chugai Pharmaceutical : Personnel Changes | PU |
| 2022 | Chugai Pharmaceutical : Partial Revision of the Basic Alliance Agreement with Roche | PU |
| 2022 | Chugai Pharmaceutical : Supplementary Materials | PU |
| 2022 | Chugai Pharmaceutical : 2Q Results (Jan-Jun 2022) | PU |
| 2022 | Chugai Pharmaceutical : F. Hoffmann-La Roche Announces Half Year Results 2022 | PU |
| 2022 | Chugai Pharmaceutical : Conference on FY2022.12 2Q Financial Results | PU |
| 2022 | Chugai's Osteoporosis Agent Edirol Launched in China | AQ |
| 2022 | Chugai Pharmaceutical Continues to be Listed for All ESG Indices Selected by GPIF | AQ |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Primary Analysis of Japanese Phase III Clinical Trial.. | AQ |
| 2022 | Chugai Pharmaceutical Co., Ltd. - New Data from Phase III HAVEN 6 Study Reinforce Favor.. | AQ |
| 2022 | New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile .. | AQ |
| 2022 | Chugai Pharmaceutical : Primary Analysis of Japanese Phase III Clinical Trial of Hemlibra .. | PU |
| 2022 | Chugai Pharmaceutical : New Data from Phase III HAVEN 6 Study Reinforce Favorable Safety a.. | PU |
| 2022 | New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile .. | AQ |
| 2022 | Chugai Pharmaceutical : Script (including Q&A) | PU |
| 2022 | Chugai Pharmaceutical : Presentation | PU |
| 2022 | Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo.. | AQ |
| 2022 | Chugai Pharmaceutical : Obtains Regulatory Approval for Hemlibra for Additional Indication.. | PU |
| 2022 | Chugai Pharmaceutical : Obtains Partial Change Approval for Neutrogin and Avastin Based on.. | PU |
| 2022 | Chugai Pharmaceutical : Anti-CD20 Monoclonal Antibody Rituxan Approved for the Prevention .. | PU |
| 2022 | Chugai Pharmaceutical : Notice of Filing an Appeal in Patent Infringement Lawsuit concerni.. | PU |
| 2022 | Chugai Receives DX Grand Prix 2022 Awards in Digital Transformation Stocks (DX Stocks) .. | AQ |
| 2022 | Chugai Supports the Japan Climate Initiative's Calling to Raise Renewable Energy Target | AQ |
| 2022 | Chugai Obtains Regulatory Approval for FoundationOne CDx Cancer Genomic Profile to be U.. | AQ |
| 2022 | Beijing IP Court Hears China's First Patent Linkage Case | AQ |
| 2022 | Chugai Pharmaceutical : Personnel Change | PU |
| 2022 | Chugai Pharmaceutical : Annual report 2021 | PU |
| 2022 | Chugai Launches Vabysmo Intravitreal Injection 120 mg/mL for the Treatment of Age-relat.. | AQ |
| 2022 | Judgement On The First Drug Patent Linkage Lawsuit In China Is Issued | AQ |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Notice of Completion of Disposal of Treasury Shares a.. | AQ |
| 2022 | Chugai Pharmaceutical : Notice of Completion of Disposal of Treasury Shares as Restricted .. | PU |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
